Harrow Health, Inc. Q3 2025 Earnings Recap

HROW Q3 2025 November 12, 2025

Get alerts when HROW reports next quarter

Harrow experienced robust revenue growth in Q3 2025, driven by strong performances from key products, particularly VEVYE and IHEEZO, while significantly enhancing market access through new payer agreements.

Earnings Per Share Beat

$0.33 vs $0.22 est.

+50.0% surprise

Revenue Miss

71638000 vs 88026430 est.

-18.6% surprise

Market Reaction

1-Day -1.43%

5-Day +3.02%

30-Day +18.89%

See HROW alongside your other holdings

Add to your portfolio — free

Key Takeaways

VEVYE achieved a remarkable 22% quarter-over-quarter revenue increase, bolstered by new preferred product status on multiple formularies starting January 2026.
IHEEZO reported a solid 20% quarterly revenue growth, despite typical seasonal slowdowns.
The company is set to launch four new products over the next two years, positioning Harrow for sustained growth and market expansion.
TRIESENCE is gaining traction in the retina market and is expected to recover in Q4 and 2026, following new leadership strategies.
The strategic acquisition of Melt Pharmaceuticals is on track, signaling further growth opportunities.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HROW on AllInvestView.

Next Q1 2026